Skip to main content
. 2022 Jun 18;13(2):739–753. doi: 10.1016/j.apsb.2022.06.011

Figure 6.

Figure 6

Lipid lowering efficacy and safety evaluation of 326E in monkeys with hyperlipidemia. (A) Schematic diagram of 326E treatment in rhesus monkey. Briefly, 6–20 years old male rhesus monkey with mild or moderate hyperlipidemia for more than 2 years (LDL-C:1.94–2.45 mmol/L) were selected, and oral treated with Veh, atorvastatin (atorva, 2.4 mg/kg/day) or 326E (20 mg/kg/day). n = 3 monkey per group; (B)–(C) Body weight change after 2 weeks treatment; (D)–(K) Plasma levels of TG (D), TC (F), LDL-C (H), ApoB100 (J) in rhesus monkey before and after 2 weeks treatment; percentage lipid lowering effect were showed compared to baseline TG (E), TC (G), LDL-C (I), ApoB100 (K) were shown; (L)–(M) Pharmacokinetic curve in each monkey (M1, M2, M3) was shown after the first dose of 326E at indicated time (L), and percentage of LDL-C lowering after 326E treated for 2 weeks in each monkey (M); (N)–(O) Plasma levels of ALT (N) and AST (O) before and after 326E or atorvastatin treatment. Data are mean ± SEM; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, Veh compared to 326E; #P < 0.05, ##P < 0.01, ###P < 0.001, Veh compared to atorva.